A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection
Clinical trial NCT07142200 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07142200
- Sponsor
- RenJi Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-01
- Primary completion
- 2026-06-30
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.